Empiric oral antibiotic therapy for febrile neutropenic cancer patients has been suggested as a means to decrease hospitalization, but the safety of this approach has not been adequately studied in children. We compared continued iv antibiotic therapy with switching treatment to orally administered cefixime in a group of selected febrile neutropenic children for whom blood cultures were sterile after 48 h of incubation. Two hundred episodes of febrile neutropenia were studied (156 patients), and 100 episodes were randomized to receive each treatment. Failure to respond to therapy was defined by documented or suspected bacterial infection, recurrent fever, or discontinuation of assigned therapy for any reason before neutropenia resolved. Rates of treatment failure were similar in the oral cefixime group (28%) and in the iv antibiotic group (27%; ). Results support the safety of oral cefixime therapy for low-risk febrile neutropenic children, a P p 1.0 therapeutic approach that would facilitate earlier outpatient management and decrease the costs of treatment.
M A J O R A R T I C L E
Oral Cefixime Is Similar to Continued Intravenous Antibiotics in the Empirical Treatment of Febrile Neutropenic Children with Cancer has prompted attempts to define criteria for early termination of iv antibiotics. In an early study, neutropenic cancer patients who had no identified source of infection and were afebrile after 7 days of treatment were randomized to continue or to discontinue antibiotic therapy [2] . An unacceptable incidence of serious infections in the patients who discontinued therapy reinforced the practice of continuing parenteral therapy until neutropenia resolved. More recently, several studies have suggested that empiric iv antibiotics can be discontinued in selected neutropenic patients who have responded to initial treatment [3] [4] [5] [6] [7] [8] [9] [10] . However, these studies have used varying selection criteria, and there are few published data from randomized, controlled studies documenting the safety of this practice [11] .
The availability of oral antimicrobial drugs that have broad activity against common pathogens may provide an attractive alternative to prolonged iv antibiotics for the treatment of febrile neutropenia. We hypothesized that patients who had no direct evidence of infection after initial evaluation and met criteria placing them at relatively low risk of breakthrough bacteremia could be safely switched to oral antibiotics. This approach was viewed as providing a greater margin of safety than discontinuing antibiotic therapy and, if proven safe, would permit outpatient management to begin earlier. Cefixime was chosen to evaluate this hypothesis because of its broad spectrum of activity (including against most strains of streptococcal and gram-negative enteric pathogens, but not Staphylococcus species or Pseudomonas aeruginosa), its record of safe use in children, and its lack of activity against anaerobic bacteria that may provide natural resistance against intestinal colonization by more invasive pathogens [12] [13] [14] [15] . We conducted a randomized clinical trial to determine if switching to oral antibiotic therapy would produce results similar to those for to continued iv antibiotic therapy in neutropenic children with cancer and unexplained fever.
PATIENTS AND METHODS

Patient selection.
Patients were from the population of childhood cancer patients (ages 6 months to 21 years) at St. Jude Children's Research Hospital, Memphis, Tennessee, who were hospitalized for febrile neutropenia from 24 January 1991 through 2 June 1995. Neutropenia was defined as an absolute neutrophil count (polymorphonuclear cells and band forms) of !500 cells/mL of blood, and fever as a single oral or axillary temperature у38.3ЊC, or a temperature у38.0ЊC for 1 h. At patient admission, a minimum of 2 blood specimens and specimens of throat and anterior nares secretions, stool, and urine were obtained for bacterial and fungal cultures. Patients were initially managed according to institutional guidelines, which specified administration of iv tobramycin (or amikacin, in the early years of the study), ticarcillin, and vancomycin. Ceftazidime and vancomycin were suggested for patients with renal dysfunction and those receiving nephrotoxic chemotherapy.
Patients became eligible for randomization to cefixime therapy or continued iv antibiotic therapy if cultures of the initial blood specimens were sterile after 48 h of incubation. According to the protocol, patients were not enrolled 172 h after the initial blood specimens were obtained for culture. Exclusion criteria, other than allergy to cephalosporin or penicillin, were designed to identify patients with a higher risk of breakthrough bacteremia and comprised the following: documentation of P. aeruginosa or methicillin-resistant Staphylococcus aureus in admission surveillance cultures or any culture obtained during the preceding 12 weeks; evidence of pneumonia on routine chest radiographs performed within the previous 24 h; clinical or radiographic findings suggestive of a focus of bacterial infection; hypotension requiring fluid or vasopressor therapy; or severe mucositis (grade 3 stomatitis or diarrhea according to the National Cancer Institute Common Toxicity Criteria: very limited eating or talking, 17 loose stools in a day, orthostatic hypotension, or requirement for iv fluid replacement). Eligible patients could be enrolled during a maximum of 5 separate neutropenic episodes if there was an interval of у12 weeks between episodes. This protocol was approved by the hospital's Institutional Review Board, and informed consent was obtained before enrollment. The protocol is available on request.
Study design and treatment. The study schema is summarized in figure 1 . Eligible patients were randomly assigned to continue the iv antibiotic regimen or to change to oral cefixime. To achieve balance in the 2 treatment groups with respect to patient characteristics that we believed were most likely to affect the risk of breakthrough bacteremia, patients were stratified to the degree mathematically feasible [16] . By use of a customized computer program and hierarchical rules, patients were stratified according to the following criteria: absolute neutrophil count !100 cells/mL; expected duration of neutropenia у5 days; "nonstandard" initial empiric antibiotic regimen; presence of an indwelling venous catheter; diagnosis of acute myeloid leukemia; and persistent fever at randomization. There was no intent to analyze outcomes within strata; we recognized that most of the possible 64 stratum groups would be of insufficient size to permit separate analyses.
Patients assigned to oral therapy received cefixime suspension (Suprax, Wyeth-Ayerst Laboratories), which produces more consistent absorption than does the tablet form [17] . Doses of 4 mg/kg were given every 12 h, starting at the end of the last infusion of iv antibiotic, and were repeated once if the patient vomited within 2 h. Patients receiving oral cefixime were switched to iv therapy in the event of treatment failure, as defined below.
Patients assigned to continued iv antibiotics received tobramycin 60 mg/m 2 imum daily dose, 4 g), each given every 6 h for the duration of the neutropenic episode. For patients with renal dysfunction, ceftazidime was given every 8 h at a dosage of 1.5 g/m 2 (maximum daily dose, 6 g). The iv regimen was changed to ceftazidime monotherapy if fever persisted after 4 days of therapy because of potential toxicity associated with the anticipated need to add amphotericin B. In both groups, amphotericin B was started if the patient had fever after 7 days of treatment. All patients received trimethoprim-sulfamethoxazole (TMP-SMZ) as prophylaxis against Pneumocystis carinii (TMP 150 mg/m 2 in 2 divided doses on 3 consecutive days each week). In accord with institutional guidelines, those patients who received у7 days of iv antibiotics and were afebrile for a minimum of 4 consecutive days could be treated with oral TMP-SMZ alone (300 mg/m 2 of TMP daily; maximum, 320 mg). Protocol-directed antibiotic treatment in both groups was continued until neutropenia resolved.
Patients were examined by a physician or nurse practitioner, and complete blood count and differential were performed daily. Laboratory studies, which were repeated at least every 3 days after the initial evaluation, were as follows: surveillance cultures, blood urea nitrogen and serum creatinine levels, total bilirubin level, aspartate aminotransferase level, and alanine aminotransferase levels. Although the protocol specified continued hospitalization for study patients, some children were discharged early by their physicians. These patients were required to visit the clinic daily and to keep a log of temperatures at 4-h intervals, in accord with protocols for inpatient care.
Assessment of treatment response. Successful completion of oral therapy required resolution of neutropenia without the addition of other antibiotics and without the occurrence of any of the following events: recurrence of fever after у24 h without a recorded temperature 138.0ЊC (continuous, persistent fever did not define treatment failure); bacteremia (growth of bacteria other than coagulase-negative staphylococci from у1 blood specimen, or growth of the same species of coagulasenegative staphylococci from у2 blood specimens obtained in a 24-h period); culture-documented or suspected localized bacterial infection; a new pulmonary infiltrate other than atelectasis; colonization with methicillin-resistant S. aureus or P. aeruginosa detected after randomization, clinical features suggestive of sepsis; and onset of severe mucositis (as defined previously) in association with a temperature of у38.3ЊC. In statistical analyses, patients who discontinued participation or were taken off the study by their physicians were considered to have failed to respond to therapy.
To permit comparisons between the 2 study groups, the same criteria for treatment failure were applied to patients receiving iv therapy. Orally treated patients who had any of the events defined above were immediately switched to iv antibiotics, but no change in treatment was mandated for patients who failed to respond to continued iv therapy.
Statistical design. The safety of oral cefixime therapy was analyzed primarily by comparing the incidence of cultureproven bacteremia in the 2 groups during the period from the first antibiotic dose after protocol enrollment until the resolution of neutropenia. To maintain statistical power and also detect clinically significant differences in the 2 groups as early as possible, we determined rates of breakthrough bacteremia using a multistage design, with 5 analyses equally spaced through the study period (4 interim analyses and a final analysis) [18] . The sample size was designed to detect with 95% power a rate of breakthrough bacteremia 120% among patients assigned to receive the oral regimen. This rate corresponds to an increase of 118% in the absolute rate of breakthrough bacteremia among patients assigned to the oral regimen compared with the estimated rate among patients assigned to the iv regimen (2% among patients receiving vancomycin, ticarcillin, and an aminoglycoside at our hospital [19] ). The estimated number of episodes required per group in a fixed sample size study ( ) was increased by 20% to maintain statistical power n p 84 in the 5-stage analysis.
We also compared the proportions of subjects who successfully completed the 2 types of therapy between the 2 treatment groups and among subpopulations that were defined by specific patient characteristics at enrollment. The proportions of subjects who completed therapy successfully were compared with use of Fisher's exact test. Differences in the medians of continuous measurements were tested with the Kruskal-Wallis procedure. Two-sided tests were used.
RESULTS
During the 53-month study period, 433 episodes of febrile neutropenia (in 308 patients) met the eligibility criteria (figure 2). Of these, 200 episodes (in 156 patients) were randomly assigned to treatment with oral or continued iv antibiotic ther- Indwelling intravascular catheter, n 84 87
Afebrile for 124 h consecutively at entry, n 67 65
Active underlying disease (induction, relapse), n 53 52
NOTE. None of the characteristics were significantly different between treatment groups except for the distribution of races ( ). ANC, absolute neutrophil count. P p .02 apy after informed consent was obtained. Nonenrollment of eligible patients by physicians (135 episodes) or parents of patients (86 episodes) accounted for the majority of failures to enroll. The primary reason cited by physicians for nonenrollment was protocol restrictions that precluded otherwise planned early discharge of patients judged to be at low risk of infection. Eleven patients were not identified within 72 h after therapy was started, and initial blood cultures were not obtained for 1 patient.
Characteristics of the treatment groups are shown in table 1. Approximately one-half of the children were receiving remission-induction therapy or treatment for relapse of underlying disease. In almost two-thirds of the study episodes, absolute neutrophil counts were !100 cells/mL. Of the patient characteristics compared, the only significant difference between groups was race ( ); however, there was no dif-P p .02 ference in rates of treatment failure by race ( ). Two P p .41 patients who represented protocol violations (one of whom had an hematologic disorder rather than cancer and another who was incorrectly continued on iv therapy after randomization to cefixime) are included in the analyses in accord with the intent-to-treat principle. Both of these episodes resolved uneventfully.
Treatment responses: safety. The observed rate of breakthrough bacteremia was 1% among the episodes assigned to oral treatment (95% CI, 0.03-5), and 0.5% for the study group as a whole. The single instance of breakthrough bacteremia occurred in a 7-year-old girl with leukemia. This child had an absolute neutrophil count of zero at enrollment and thereafter. Her fever resolved soon after admission and initiation of empiric iv antibiotics. Thirty hours after her randomization to oral cefixime (after 3 doses), she had rigors and fever to 40.7ЊC (measured orally). Treatment with iv antibiotics was reinstituted immediately, and she promptly became afebrile. Her recovery was uneventful. Specimens obtained from both lumens of the central venous catheter grew cefixime-resistant Escherichia coli (11 cfu/mL of blood from each lumen; the isolate was susceptible to ceftazidime and aminoglycosides). Culture of peripheral blood specimens was sterile, suggesting a catheter-related infection [20] . Treatment failures. Of the 100 episodes assigned to cefixime, patients successfully completed oral therapy in 72. The success rate for the intravenously treated episodes-based on the criteria developed for oral therapy-was similar (73 of 100 episodes, ; observed difference 1%; 95% CI, Ϫ13 to P p 1.0 ϩ11). In each of the treatment groups, there were 5 patients classified as failing to respond to therapy that were actually related to physician or parent preferences (table 2). Recurrent fever was the predominant cause of treatment failure in patients treated with either cefixime (17 episodes, including the child Recurrent fever 16 16 Recurrent fever with breakthrough bacteremia 0 1
New focus of infection 2 3
New pulmonary infiltrate 2 0
New colonization with Pseudomonas aeruginosa 2 2 Skin lesions suggesting septic emboli 0 1
Parent or patient requested removal from study 2 1
Attending physician requested removal from study for reasons not specified by protocol 3 4
NOTE. There were no statistically significant differences in outcome by treatment group.
with fever and breakthrough bacteremia) or iv antibiotics (16 episodes). One intravenously treated patient failed to respond to therapy (recurrent fever) after meeting the study criteria for change to oral TMP-SMZ therapy. Figure 3 illustrates the temporal pattern of treatment failure for the 2 groups. Both failures of therapy and resolution of neutropenia tended to occur earlier after randomization for orally treated patients. Consequently, orally treated patients reached a study end point (failure to respond to therapy or resolution of neutropenia) in a shorter period of time than those assigned to iv therapy (median of 3 vs. 4 days to an end point;
). P p .01 Rates of treatment failure were analyzed separately for patients with persistent fever at study entry and those with absolute neutrophil counts of !100 cells/mL (table 3) , as these subgroups may be at increased risk. Within these subpopulations, there were no significant differences between treatment groups. Further, rates of treatment failure were not appreciably higher for children with persistent fever than for those without. As expected, treatment failure rates were higher in children with severe neutropenia than in those without severe neutropenia (46 of 131 vs. 9 of 69;
). P p .0008 The median duration of neutropenia after randomization was 5 days (range, 1-41 days) for the patients treated with cefixime and 5.5 days (range, 1-52 days) for patients treated with iv therapy ( ). Patients in the cefixime group who P p .18 failed to respond to therapy were hospitalized for a median of 7 days, compared with 5 days for patients assigned to continued iv antibiotics who met the same criteria for treatment failure ( ). All patients who were switched from oral to iv ther-P p .26 apy because of treatment failure responded when fever and neutropenia resolved.
Similar numbers of patients in the 2 treatment groups required empirical therapy with amphotericin B (9 patients who continued iv therapy and 10 who received oral cefixime). Disseminated Candida tropicalis infection was documented in 1 patient assigned to oral therapy.
Adverse effects of therapy. Both treatment regimens were well tolerated. As shown in table 4, side effects of antibiotic therapy, with the exception of diarrhea, were distributed evenly between the 2 groups. Nine patients who received cefixime had diarrhea, compared with 3 patients who continued iv therapy ( ). Differences between the 2 groups for duration of P p .13 diarrhea approached statistical significance ( ). P p .07
DISCUSSION
Recently, 3 randomized studies compared initial oral with iv antibiotics as empiric therapy for febrile neutropenic episodes, primarily in adults with breast cancer or other solid tumors [21] [22] [23] . These studies found that therapies with oral ofloxacin [21] or ciprofloxacin plus amoxicillin-clavulanate [22, 23] yielded results similar to those for iv antibiotic therapies. Another study conducted in Pakistan compared oral ofloxacin with iv antibiotics in adults with leukemia and solid tumors, and also reported equivalence of therapies; however, there were several deaths in each treatment arm [24] . In a Brazilian study, low-risk neutropenic children with solid tumors or stage I or II lymphoma fared as well when initially treated with oral ciprofloxacin as when treated with iv ceftriaxone; no deaths from infection occurred in either group [25] . None of these patients had Hickman catheters and none received high-dose chemotherapy. In a nonrandomized trial conducted in Dallas, Texas, low-risk febrile neutropenic children with cancer in remission were managed with 1 dose of iv ceftazidime followed by oral ciprofloxacin [26] . Streptococcal bacteremia (initial viridans streptococcal bacteremia and breakthrough Streptococcus pneumoniae bacteremia) occurred in 2 children (4% of 45 evaluated episodes) who had uncomplicated recovery.
In considering alternatives to the conventional management of febrile neutropenia in an expanded spectrum of children with cancer, including children with leukemia not in remission, we believe that the initial use of iv antibiotics is prudent. This approach avoids the prospect of treating substantial numbers of bacteremic, neutropenic children with an oral antibiotic regimen that is potentially less potent than standard iv regimens. At our institution, 14% of children evaluated for neutropenia and unexplained fever without other presenting indications of bacteremia have blood cultures that are positive for bacterial pathogens [19] . We based the duration of initial iv therapy on a review of results from our clinical microbiology laboratory, which indicated that growth was detected within 48 h of incubation for virtually all blood specimens that ultimately yielded bacterial pathogens. Results of surveillance surface cultures also become available within this time frame. We hypothesized that patients who had cultures of initial blood specimens that showed no growth after 48 h and who did not have specific risk factors for breakthrough bacteremia could be switched to an oral antibiotic without significantly increasing the risk of serious infections compared with patients who completed a course of iv therapy.
Our randomized trial of oral cefixime versus continued iv antibiotics supports this hypothesis. The overall rate of breakthrough bacteremia was 0.5%, and 1% in the oral cefixime group; the expected rate in an unselected population of febrile neutropenic children managed with iv antibiotics is 2% [19] . Therefore our selection criteria were successful in identifying a population with a low risk of breakthrough bacteremia. The 1 case of bacteremia in a child assigned to cefixime, however, underscores the need to carefully observe pediatric cancer patients who are managed with oral antibiotic therapy. Rates of treatment failure, based on criteria designed to identify the possibility of undetected bacteremia, were almost identical for patients who were switched to the oral antibiotic and those who continued the iv regimen. There were no deaths during the study, and all children who were switched from oral to iv therapy responded well. Increase in total bilirubin level у2 times ULN, n 0 0
NOTE. There were no statistically significant differences in outcome by treatment group. ULN, upper limit of normal.
At the time when they developed their febrile episodes, all patients in this study were receiving TMP-SMZ on 3 consecutive days each week as prophylaxis against P. carinii ("intermittent" prophylaxis) and continued to receive this regimen during their participation in this trial. A previous study performed at our institution showed that patients who recently became septic who subsequently received daily TMP-SMZ as prophylaxis against P. carinii infection were significantly less likely to have recurrent episodes of sepsis than were patients who did not receive prophylaxis [27] . In another study from our institution, the intermittent use of TMP-SMZ was not found to increase the risk of bacterial infections while lowering the risk of fungal infections, compared with the incidence of infection in neutropenic patients receiving daily therapy [28] . Therefore, the use of intermittent TMP-SMZ prophylaxis may have contributed to the overall low incidence of breakthrough bacteremia observed in this study.
We included a wider range of patients than have been reported in many previous studies of oral antibiotic therapy or early discontinuation of iv therapy. In our study, approximately one third of the episodes treated in each group were associated with continued fever at the time of randomization. There was no difference in treatment failure rates for these patients compared with those whose fever had resolved before randomization (for patients given oral treatment, 11 ). This suggests that P p .81 outpatient management with oral antibiotics may be effective for patients who have persistent fever after initially receiving iv therapy. Rapid resolution of fever after the initiation of iv antibiotics may indicate bacterial infection, whereas persistent fever may indicate a nonbacterial infection or noninfectious process.
Our study also included a large proportion of children with profound neutropenia (almost two-thirds of study subjects had absolute neutrophil counts of !100 cells/mL). It is of interest that we did not detect any relative increase in treatment failure rates in the group who received oral therapy versus those who received iv therapy among the children with profound neutropenia. However, treatment was more likely to fail for children with profound neutropenia than for children without profound neutropenia. Exclusion of patients with severe mucositis may have accounted for the low incidence of breakthrough bacteremia in children with severe neutropenia [29] . Our findings are in accord with the results of a pilot Canadian study in which switching to treatment with oral cefixime was successful for 20 (87%) of 23 pediatric cancer patients who were afebrile after receiving 72 h of iv antibiotic therapy [30] . Three of the patients studied had recurrent fever, which responded to resumption of iv antibiotics in 2 patients and was believed to be caused by relapsed leukemia in the third patient. In a study undertaken in Dallas, investigators estimated that $5058 was saved for each neutropenic child who was discharged early from the hospital because they had been switched to oral antibiotic therapy or because their therapy had been discontinued [5] . By use of a comparative randomized design, the trial described here establishes that the course disease in lowrisk, neutropenic children who are switched to oral cefixime is similar to the course of disease in those who continue iv antibiotic therapy, and that it is associated with few adverse events. In contrast, a study that randomized neutropenic adults with cancer to receive inpatient iv antibiotics or outpatient oral clindamycin plus ciprofloxacin had to be terminated early because of the high incidence of nephrotoxicity in patients who received this oral therapy [31] .
We have modified our institutional guidelines for the treatment of febrile neutropenia on the basis of the results of this randomized trial. Empirical oral antibiotic therapy is now rec-ommended for neutropenic patients with unexplained fever who meet the entry criteria used in this study. To date, the single serious treatment failure noted in our practice was a patient who did not meet these criteria (the patient was colonized with P. aeruginosa) and developed breakthrough P. aeruginosa bacteremia while receiving cefixime.
